1
|
Non-kinase targeting of oncogenic c-Jun N-terminal kinase (JNK) signaling: the future of clinically viable cancer treatments. Biochem Soc Trans 2022; 50:1823-1836. [PMID: 36454622 PMCID: PMC9788565 DOI: 10.1042/bst20220808] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 10/28/2022] [Accepted: 11/15/2022] [Indexed: 01/09/2023]
Abstract
c-Jun N-terminal Kinases (JNKs) have been identified as key disease drivers in a number of pathophysiological settings and central oncogenic signaling nodes in various cancers. Their roles in driving primary tumor growth, positively regulating cancer stem cell populations, promoting invasion and facilitating metastatic outgrowth have led JNKs to be considered attractive targets for anti-cancer therapies. However, the homeostatic, apoptotic and tumor-suppressive activities of JNK proteins limit the use of direct JNK inhibitors in a clinical setting. In this review, we will provide an overview of the different JNK targeting strategies developed to date, which include various ATP-competitive, non-kinase and substrate-competitive inhibitors. We aim to summarize their distinct mechanisms of action, review some of the insights they have provided regarding JNK-targeting in cancer, and outline the limitations as well as challenges of all strategies that target JNKs directly. Furthermore, we will highlight alternate drug targets within JNK signaling complexes, including recently identified scaffold proteins, and discuss how these findings may open up novel therapeutic options for targeting discrete oncogenic JNK signaling complexes in specific cancer settings.
Collapse
|
2
|
Cho H, Hah JM. A Perspective on the Development of c-Jun N-terminal Kinase Inhibitors as Therapeutics for Alzheimer's Disease: Investigating Structure through Docking Studies. Biomedicines 2021; 9:biomedicines9101431. [PMID: 34680547 PMCID: PMC8533360 DOI: 10.3390/biomedicines9101431] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Revised: 09/28/2021] [Accepted: 10/08/2021] [Indexed: 11/26/2022] Open
Abstract
c-Jun N-terminal kinase (JNK) plays an important role in cell death caused by various stimuli. Because the isoform JNK3 is mainly expressed in the brain, it is believed to play a pivotal role in various neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), which still lack plausible therapeutics. To develop a novel and selective JNK3 inhibitor, we conducted a decadal review (2011 to 2021) of published articles on JNK inhibitors, particularly those focusing on a structural perspective and docking insights. We observed the structures of three isoforms of JNK, namely holo-proteins and co-crystal structures, with JNK3 inhibitors and summarized the significant structural aspects of selective JNK3 inhibitors as AD therapeutics.
Collapse
Affiliation(s)
- Hyunwook Cho
- Department of Pharmacy, College of Pharmacy, Hanyang University, Ansan 15588, Korea;
- Center for Proteinopathy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan 15588, Korea
| | - Jung-Mi Hah
- Department of Pharmacy, College of Pharmacy, Hanyang University, Ansan 15588, Korea;
- Center for Proteinopathy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan 15588, Korea
- Correspondence: ; Tel.: +82-31-400-5803
| |
Collapse
|
3
|
Duong MTH, Lee JH, Ahn HC. C-Jun N-terminal kinase inhibitors: Structural insight into kinase-inhibitor complexes. Comput Struct Biotechnol J 2020; 18:1440-1457. [PMID: 32637042 PMCID: PMC7327381 DOI: 10.1016/j.csbj.2020.06.013] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2020] [Revised: 06/07/2020] [Accepted: 06/07/2020] [Indexed: 12/12/2022] Open
Abstract
The activation of c-Jun N-terminal kinases (JNKs) plays an important role in physiological processes including neuronal function, immune activity, and development, and thus, JNKs have been a therapeutic target for various diseases such as neurodegenerative diseases, inflammation, and cancer. Efforts to develop JNK-specific inhibitors have been ongoing for several decades. In this process, the structures of JNK in complex with various inhibitors have contributed greatly to the design of novel compounds and to the elucidation of structure-activity relationships. Almost 100 JNK structures with various compounds have been determined. Here we summarize the information gained from these structures and classify the inhibitors into several groups based on the binding mode. These groups include inhibitors in the open conformation and closed conformation of the gatekeeper residue, non-ATP site binders, peptides, covalent inhibitors, and type II kinase inhibitors. Through this work, deep insight into the interaction of inhibitors with JNKs can be gained and this will be helpful for developing novel, potent, and selective inhibitors.
Collapse
Affiliation(s)
- Men Thi Hoai Duong
- Department of Pharmacy, Dongguk University-Seoul, Goyang, Gyeonggi 10326, South Korea
| | - Joon-Hwa Lee
- Department of Chemistry and RINS, Gyeongsang National University, Jinju, Gyeongnam 52828, South Korea
| | - Hee-Chul Ahn
- Department of Pharmacy, Dongguk University-Seoul, Goyang, Gyeonggi 10326, South Korea
| |
Collapse
|
4
|
Choi SY, Kim HD, Park JU, Park SA, Kim JH. Cp*Co(III)-Catalyzed γ-Selective C-H Allylation/Hydroamination Cascade for the Synthesis of Dihydroisoquinolines. Org Lett 2019; 21:10038-10042. [PMID: 31794237 DOI: 10.1021/acs.orglett.9b03977] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A Cp*Co(III)-catalyzed γ-selective C-H allylation/hydroamination cascade toward the synthesis of 3,4-dihydroisoquinolines (DHIQs) has been successfully developed, starting from NH ketimines and allyl carbonates. Notably, highly efficient and γ-selective C-H allylations were accomplished using γ-substituted allyl reagents, thus overcoming the issues of poor α/γ selectivity and low reactivity of previous transition metal-catalyzed C-H allylations. The stereochemistry of allyl carbonates was a crucial factor, and synthesis of the DHIQs was achieved using (Z)-allyl carbonates.
Collapse
Affiliation(s)
- Suh Young Choi
- Department of Chemistry (BK21 Plus), Research Institute of Natural Science , Gyeongsang National University , 52828 , Jinju , Korea
| | - Hyeon Dae Kim
- Department of Chemistry (BK21 Plus), Research Institute of Natural Science , Gyeongsang National University , 52828 , Jinju , Korea
| | - Jong-Un Park
- Department of Chemistry (BK21 Plus), Research Institute of Natural Science , Gyeongsang National University , 52828 , Jinju , Korea
| | - Sun-A Park
- Department of Chemistry (BK21 Plus), Research Institute of Natural Science , Gyeongsang National University , 52828 , Jinju , Korea
| | - Ju Hyun Kim
- Department of Chemistry (BK21 Plus), Research Institute of Natural Science , Gyeongsang National University , 52828 , Jinju , Korea
| |
Collapse
|
5
|
Tuffaha GO, Hatmal MM, Taha MO. Discovery of new JNK3 inhibitory chemotypes via QSAR-Guided selection of docking-based pharmacophores and comparison with other structure-based pharmacophore modeling methods. J Mol Graph Model 2019; 91:30-51. [PMID: 31158642 DOI: 10.1016/j.jmgm.2019.05.015] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Revised: 05/13/2019] [Accepted: 05/17/2019] [Indexed: 12/21/2022]
|
6
|
Substituent effects on axial chirality in 1-aryl-3,4-dihydroisoquinolines: controlling the rate of bond rotation. Tetrahedron 2016. [DOI: 10.1016/j.tet.2016.01.037] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
7
|
JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases. Future Med Chem 2015; 7:2065-86. [PMID: 26505831 DOI: 10.4155/fmc.15.132] [Citation(s) in RCA: 136] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
JNK pathway regulates various physiological processes including inflammatory responses, cell differentiation, cell proliferation, cell death, cell survival and expression of proteins. Deregulation of JNK is linked with various diseases including neurodegenerative disease, autoimmune disease, diabetes, cancer, cardiac hypertrophy and asthma. Three distinct genes JNK1, JNK2 and JNK3 have been identified as regulator of JNK pathway. JNK1 and JNK2 have broad tissue distribution and play a potential role in insulin resistance, inflammation and cell signaling. JNK3 is predominantly found in the CNS neurons, making it an attractive target for neurodegenerative disorders. In this review, we summarize the evidence supporting JNK as a potent therapeutic target, and small molecules from various chemical classes as JNK inhibitors.
Collapse
|
8
|
The Bright Future of Unconventional σ/π-Hole Interactions. Chemphyschem 2015; 16:2496-517. [DOI: 10.1002/cphc.201500314] [Citation(s) in RCA: 475] [Impact Index Per Article: 52.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Indexed: 01/25/2023]
|
9
|
Wityak J, McGee KF, Conlon MP, Song RH, Duffy BC, Clayton B, Lynch M, Wang G, Freeman E, Haber J, Kitchen DB, Manning DD, Ismail J, Khmelnitsky Y, Michels P, Webster J, Irigoyen M, Luche M, Hultman M, Bai M, Kuok ID, Newell R, Lamers M, Leonard P, Yates D, Matthews K, Ongeri L, Clifton S, Mead T, Deupree S, Wheelan P, Lyons K, Wilson C, Kiselyov A, Toledo-Sherman L, Beconi M, Muñoz-Sanjuan I, Bard J, Dominguez C. Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors. J Med Chem 2015; 58:2967-87. [PMID: 25760409 DOI: 10.1021/jm5013598] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Through medicinal chemistry lead optimization studies focused on calculated properties and guided by X-ray crystallography and computational modeling, potent pan-JNK inhibitors were identified that showed submicromolar activity in a cellular assay. Using in vitro ADME profiling data, 9t was identified as possessing favorable permeability and a low potential for efflux, but it was rapidly cleared in liver microsomal incubations. In a mouse pharmacokinetics study, compound 9t was brain-penetrant after oral dosing, but exposure was limited by high plasma clearance. Brain exposure at a level expected to support modulation of a pharmacodynamic marker in mouse was achieved when the compound was coadministered with the pan-cytochrome P450 inhibitor 1-aminobenzotriazole.
Collapse
Affiliation(s)
- John Wityak
- †CHDI Foundation, Inc., 6080 Center Drive, Suite 100, Los Angeles, California 90045, United States
| | - Kevin F McGee
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Michael P Conlon
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Ren Hua Song
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Bryan C Duffy
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Brent Clayton
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Michael Lynch
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Gwen Wang
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Emily Freeman
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - James Haber
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Douglas B Kitchen
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - David D Manning
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Jiffry Ismail
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Yuri Khmelnitsky
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Peter Michels
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Jeff Webster
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Macarena Irigoyen
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Michele Luche
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Monica Hultman
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Mei Bai
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - IokTeng D Kuok
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Ryan Newell
- ‡Albany Molecular Research Inc. (AMRI), 26 Corporate Circle, Albany, New York 12212-5098, United States
| | - Marieke Lamers
- §BioFocus Discovery Services, Charles River Laboratories, Chesterford Research Park, Little Chesterford, CB10 1XL, United Kingdom
| | - Philip Leonard
- §BioFocus Discovery Services, Charles River Laboratories, Chesterford Research Park, Little Chesterford, CB10 1XL, United Kingdom
| | - Dawn Yates
- §BioFocus Discovery Services, Charles River Laboratories, Chesterford Research Park, Little Chesterford, CB10 1XL, United Kingdom
| | - Kim Matthews
- §BioFocus Discovery Services, Charles River Laboratories, Chesterford Research Park, Little Chesterford, CB10 1XL, United Kingdom
| | - Lynette Ongeri
- §BioFocus Discovery Services, Charles River Laboratories, Chesterford Research Park, Little Chesterford, CB10 1XL, United Kingdom
| | - Steve Clifton
- §BioFocus Discovery Services, Charles River Laboratories, Chesterford Research Park, Little Chesterford, CB10 1XL, United Kingdom
| | - Tania Mead
- §BioFocus Discovery Services, Charles River Laboratories, Chesterford Research Park, Little Chesterford, CB10 1XL, United Kingdom
| | - Susan Deupree
- ∥Tandem Laboratories, 2202 Ellis Road, Durham, North Carolina 27703, United States
| | - Pat Wheelan
- ∥Tandem Laboratories, 2202 Ellis Road, Durham, North Carolina 27703, United States
| | - Kathy Lyons
- ⊥Pharmacokinetics Consultant to CHDI, P.O. Box 64, Holland, New York 14080, United States
| | - Claire Wilson
- #Evotec, 114 Milton Park, Abingdon, OX14 4SA, United Kingdom
| | - Alex Kiselyov
- †CHDI Foundation, Inc., 6080 Center Drive, Suite 100, Los Angeles, California 90045, United States
| | - Leticia Toledo-Sherman
- †CHDI Foundation, Inc., 6080 Center Drive, Suite 100, Los Angeles, California 90045, United States
| | - Maria Beconi
- †CHDI Foundation, Inc., 6080 Center Drive, Suite 100, Los Angeles, California 90045, United States
| | - Ignacio Muñoz-Sanjuan
- †CHDI Foundation, Inc., 6080 Center Drive, Suite 100, Los Angeles, California 90045, United States
| | - Jonathan Bard
- †CHDI Foundation, Inc., 6080 Center Drive, Suite 100, Los Angeles, California 90045, United States
| | - Celia Dominguez
- †CHDI Foundation, Inc., 6080 Center Drive, Suite 100, Los Angeles, California 90045, United States
| |
Collapse
|
10
|
Abstract
The c-Jun N-terminal kinases (JNKs) are serine/threonine kinases implicated in the pathogenesis of various diseases. Recent advances in the development of novel inhibitors of JNKs will be reviewed. Significant progress in the design of JNK inhibitors displaying selectivity versus other kinases has been achieved within the past 4 years. However, the development of isoform selective JNK inhibitors is still an open task.
Collapse
Affiliation(s)
- Pierre Koch
- Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen , Auf der Morgenstelle 8, 72076 Tübingen, Germany
| | | | | |
Collapse
|
11
|
Zheng K, Iqbal S, Hernandez P, Park H, LoGrasso PV, Feng Y. Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives. J Med Chem 2014; 57:10013-30. [PMID: 25393557 PMCID: PMC4266361 DOI: 10.1021/jm501256y] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
![]()
The
c-jun N-terminal kinase 3 (JNK3) is expressed primarily in
the brain. Numerous reports have shown that inhibition of JNK3 is
a promising strategy for treatment of neurodegeneration. The optimization
of aminopyrazole-based JNK3 inhibitors with improved potency, isoform
selectivity, and pharmacological properties by structure–activity
relationship (SAR) studies utilizing biochemical and cell-based assays,
and structure-based drug design is reported. These inhibitors had
high selectivity over JNK1 and p38α, minimal cytotoxicity, potent
inhibition of 6-OHDA-induced mitochondrial membrane potential dissipation
and ROS generation, and good drug metabolism and pharmacokinetic (DMPK)
properties for iv dosing. 26n was profiled against 464
kinases and was found to be highly selective hitting only seven kinases
with >80% inhibition at 10 μM. Moreover, 26n showed
good solubility, good brain penetration, and good DMPK properties.
Finally, the crystal structure of 26k in complex with
JNK3 was solved at 1.8 Å to explore the binding mode of aminopyrazole
based JNK3 inhibitors.
Collapse
Affiliation(s)
- Ke Zheng
- Medicinal Chemistry, ‡Discovery Biology, §Crystallography/Modeling Facility, Translational Research Institute, and ∥Department of Molecular Therapeutics, Scripps Florida, The Scripps Research Institute , 130 Scripps Way, No. 2A1, Jupiter, Florida 33458, United States
| | | | | | | | | | | |
Collapse
|
12
|
New derivatives of 3,4-dihydroisoquinoline-3-carboxylic acid with free-radical scavenging, D-amino acid oxidase, acetylcholinesterase and butyrylcholinesterase inhibitory activity. Molecules 2014; 19:15866-90. [PMID: 25271427 PMCID: PMC6271642 DOI: 10.3390/molecules191015866] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2014] [Revised: 09/17/2014] [Accepted: 09/22/2014] [Indexed: 11/29/2022] Open
Abstract
A series of 3,4-dihydroisoquinoline-3-carboxylic acid derivatives were synthesised and tested for their free-radical scavenging activity using 2,2-diphenyl-1-picrylhydrazyl radical (DPPH·), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) radical (ABTS·+), superoxide anion radical (O2·−) and nitric oxide radical (·NO) assays. We also studied d-amino acid oxidase (DAAO), acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activity. Almost each of newly synthesised compounds exhibited radical scavenging capabilities. Moreover, several compounds showed moderate inhibitory activities against DAAO, AChE and BuChE. Compounds with significant free-radical scavenging activity may be potential candidates for therapeutics used in oxidative-stress-related diseases.
Collapse
|
13
|
Václavík J, Sot P, Pecháček J, Vilhanová B, Matuška O, Kuzma M, Kačer P. Experimental and theoretical perspectives of the Noyori-Ikariya asymmetric transfer hydrogenation of imines. Molecules 2014; 19:6987-7007. [PMID: 24879612 PMCID: PMC6272002 DOI: 10.3390/molecules19066987] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Revised: 05/13/2014] [Accepted: 05/21/2014] [Indexed: 11/25/2022] Open
Abstract
The asymmetric transfer hydrogenation (ATH) of imines catalyzed by the Noyori-Ikariya [RuCl(η6-arene)(N-arylsulfonyl-DPEN)] (DPEN=1,2-diphenylethylene-1,2-diamine) half-sandwich complexes is a research topic that is still being intensively developed. This article focuses on selected aspects of this catalytic system. First, a great deal of attention is devoted to the N-arylsulfonyl moiety of the catalysts in terms of its interaction with protonated imines (substrates) and amines (components of the hydrogen-donor mixture). The second part is oriented toward the role of the η6-coordinated arene. The final part concerns the imine substrate structural modifications and their importance in connection with ATH. Throughout the text, the summary of known findings is complemented with newly-presented ones, which have been approached both experimentally and computationally.
Collapse
Affiliation(s)
- Jiří Václavík
- Department of Organic Technology, Institute of Chemical Technology, Technická 5, CZ-166 28 Prague, Czech Republic
| | - Petr Sot
- Department of Organic Technology, Institute of Chemical Technology, Technická 5, CZ-166 28 Prague, Czech Republic
| | - Jan Pecháček
- Department of Organic Technology, Institute of Chemical Technology, Technická 5, CZ-166 28 Prague, Czech Republic
| | - Beáta Vilhanová
- Department of Organic Technology, Institute of Chemical Technology, Technická 5, CZ-166 28 Prague, Czech Republic
| | - Ondřej Matuška
- Department of Organic Technology, Institute of Chemical Technology, Technická 5, CZ-166 28 Prague, Czech Republic
| | - Marek Kuzma
- Laboratory of Molecular Structure Characterization, Institute of Microbiology, v.v.i., Academy of Sciences of the Czech Republic, Vídeňská 1083, CZ-142 20 Prague, Czech Republic
| | - Petr Kačer
- Department of Organic Technology, Institute of Chemical Technology, Technická 5, CZ-166 28 Prague, Czech Republic.
| |
Collapse
|
14
|
He Y, Duckett D, Chen W, Ling YY, Cameron MD, Lin L, Ruiz CH, Lograsso PV, Kamenecka TM, Koenig M. Synthesis and SAR of novel isoxazoles as potent c-jun N-terminal kinase (JNK) inhibitors. Bioorg Med Chem Lett 2013; 24:161-4. [PMID: 24332487 DOI: 10.1016/j.bmcl.2013.11.052] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2013] [Revised: 11/15/2013] [Accepted: 11/20/2013] [Indexed: 01/28/2023]
Abstract
The design and synthesis of isoxazole 3 is described, a potent JNK inhibitor with two fold selectivity over p38. Optimization of this scaffold led to compounds 27 and 28 which showed greatly improved selectivity over p38 by maintaining the JNK3 potency of compound 3. Extensive SAR studies will be described as well as preliminary in vivo data of the two lead compounds.
Collapse
Affiliation(s)
- Yuanjun He
- Department of Molecular Therapeutics, and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Derek Duckett
- Department of Molecular Therapeutics, and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Weimin Chen
- Department of Molecular Therapeutics, and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Yuan Yuan Ling
- Department of Molecular Therapeutics, and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Michael D Cameron
- Department of Molecular Therapeutics, and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Li Lin
- Department of Molecular Therapeutics, and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Claudia H Ruiz
- Department of Molecular Therapeutics, and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Philip V Lograsso
- Department of Molecular Therapeutics, and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Theodore M Kamenecka
- Department of Molecular Therapeutics, and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Marcel Koenig
- Department of Molecular Therapeutics, and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #A2A, Jupiter, FL 33458, USA.
| |
Collapse
|
15
|
Gong L, Han X, Silva T, Tan YC, Goyal B, Tivitmahaisoon P, Trejo A, Palmer W, Hogg H, Jahagir A, Alam M, Wagner P, Stein K, Filonova L, Loe B, Makra F, Rotstein D, Rapatova L, Dunn J, Zuo F, Porto JD, Wong B, Jin S, Chang A, Tran P, Hsieh G, Niu L, Shao A, Reuter D, Hermann J, Kuglstatter A, Goldstein D. Development of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): Optimization for JNK potency and physicochemical properties. Bioorg Med Chem Lett 2013; 23:3565-9. [DOI: 10.1016/j.bmcl.2013.04.029] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2013] [Revised: 04/08/2013] [Accepted: 04/12/2013] [Indexed: 11/16/2022]
|
16
|
Palmer WS, Alam M, Arzeno HB, Chang KC, Dunn JP, Goldstein DM, Gong L, Goyal B, Hermann JC, Hogg JH, Hsieh G, Jahangir A, Janson C, Jin S, Ursula Kammlott R, Kuglstatter A, Lukacs C, Michoud C, Niu L, Reuter DC, Shao A, Silva T, Trejo-Martin TA, Stein K, Tan YC, Tivitmahaisoon P, Tran P, Wagner P, Weller P, Wu SY. Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): Kinase profiling guided optimization of a 1,2,3-benzotriazole lead. Bioorg Med Chem Lett 2013; 23:1486-92. [DOI: 10.1016/j.bmcl.2012.12.047] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2012] [Revised: 12/12/2012] [Accepted: 12/13/2012] [Indexed: 11/30/2022]
|
17
|
Kobayashi K, Matsumoto N, Matsumoto K. Synthesis of 3,4-Dihydroisoquinolines by Cyclization of 1-Bromo-2-(2-isocyanoalkyl)benzenes with Butyllithium. HETEROCYCLES 2013. [DOI: 10.3987/com-12-12620] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
18
|
Subba Reddy B, Umadevi N, Narasimhulu G, Yadav J. Oxidative C–H functionalization: a novel strategy for the acetoxylation/alkoxylation of arenes tethered to 3,4-dihydroisoquinolines. Tetrahedron Lett 2012. [DOI: 10.1016/j.tetlet.2012.08.124] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
19
|
Gong L, Tan YC, Boice G, Abbot S, McCaleb K, Iyer P, Zuo F, Dal Porto J, Wong B, Jin S, Chang A, Tran P, Hsieh G, Niu L, Shao A, Reuter D, Lukacs CM, Ursula Kammlott R, Kuglstatter A, Goldstein D. Discovery of a novel series of 4-quinolone JNK inhibitors. Bioorg Med Chem Lett 2012; 22:7381-7. [PMID: 23142618 DOI: 10.1016/j.bmcl.2012.10.066] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2012] [Revised: 10/10/2012] [Accepted: 10/15/2012] [Indexed: 11/16/2022]
Abstract
A novel series of highly selective JNK inhibitors based on the 4-quinolone scaffold was designed and synthesized. Structure based drug design was utilized to guide the compound design as well as improvements in the physicochemical properties of the series. Compound (13c) has an IC(50) of 62/170 nM for JNK1/2, excellent kinase selectivity and impressive efficacy in a rodent asthma model.
Collapse
Affiliation(s)
- Leyi Gong
- Department of Medicinal Chemistry, Roche Palo Alto, Palo Alto, CA 94304, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Dong J, Shi XX, Xing J, Yan JJ. Mild and Efficient Syntheses of 1-Aryl-3,4-dihydroisoquinolines and 1-Aryl-3,4-dihydro-β-carbolines via Regiospecific β-Eliminations of the CorrespondingN-Tosyl-1,2,3,4-tetrahydroisoquinolines andN-Tosyl-1,2,3,4-tetrahydro-β-carbolines. SYNTHETIC COMMUN 2012. [DOI: 10.1080/00397911.2011.568659] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
21
|
Schepetkin IA, Kirpotina LN, Khlebnikov AI, Hanks TS, Kochetkova I, Pascual DW, Jutila MA, Quinn MT. Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors. Mol Pharmacol 2012; 81:832-45. [PMID: 22434859 DOI: 10.1124/mol.111.077446] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
In efforts to identify novel small molecules with anti-inflammatory properties, we discovered a unique series of tetracyclic indenoquinoxaline derivatives that inhibited lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 activation. Compound IQ-1 (11H-indeno[1,2-b]quinoxalin-11-one oxime) was found to be a potent, noncytotoxic inhibitor of pro-inflammatory cytokine [interleukin (IL)-1α, IL-1β, IL-6, IL-10, tumor necrosis factor (TNF)-α, interferon-γ, and granulocyte-macrophage colony-stimulating factor] and nitric oxide production by human and murine monocyte/macrophages. Three additional potent inhibitors of cytokine production were identified through further screening of IQ-1 analogs. The sodium salt of IQ-1 inhibited LPS-induced TNF-α and IL-6 production in MonoMac-6 cells with IC(50) values of 0.25 and 0.61 μM, respectively. Screening of 131 protein kinases revealed that derivative IQ-3 [11H-indeno[1,2-b]quinoxalin-11-one-O-(2-furoyl)oxime]was a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. This compound, as well as IQ-1 and three additional oxime indenoquinoxalines, were found to be high-affinity JNK inhibitors with nanomolar binding affinity and ability to inhibit c-Jun phosphorylation. Furthermore, docking studies showed that hydrogen bonding interactions of the active indenoquinoxalines with Asn152, Gln155, and Met149 of JNK3 played an important role in enzyme binding activity. Finally, we showed that the sodium salt of IQ-1 had favorable pharmacokinetics and inhibited the ovalbumin-induced CD4(+) T-cell immune response in a murine delayed-type hypersensitivity model in vivo. We conclude that compounds with an indenoquinoxaline nucleus can serve as specific small-molecule modulators for mechanistic studies of JNKs as well as a potential leads for the development of anti-inflammatory drugs.
Collapse
Affiliation(s)
- Igor A Schepetkin
- Department of Immunology and Infectious Diseases, Montana State University, Bozeman, MT 59717, USA
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Song X, Chen W, Lin L, Ruiz CH, Cameron MD, Duckett DR, Kamenecka TM. Synthesis and SAR of 2-Phenoxypyridines as novel c-Jun N-terminal kinase inhibitors. Bioorg Med Chem Lett 2011; 21:7072-5. [DOI: 10.1016/j.bmcl.2011.09.090] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2011] [Revised: 09/20/2011] [Accepted: 09/21/2011] [Indexed: 11/28/2022]
|
23
|
Bowers S, Truong AP, Neitz RJ, Neitzel M, Probst GD, Hom RK, Peterson B, Galemmo RA, Konradi AW, Sham HL, Tóth G, Pan H, Yao N, Artis DR, Brigham EF, Quinn KP, Sauer JM, Powell K, Ruslim L, Ren Z, Bard F, Yednock TA, Griswold-Prenner I. Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor. Bioorg Med Chem Lett 2011; 21:1838-43. [DOI: 10.1016/j.bmcl.2011.01.046] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2010] [Revised: 01/11/2011] [Accepted: 01/12/2011] [Indexed: 01/17/2023]
|
24
|
Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, Tóth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I. Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg Med Chem Lett 2011; 21:315-9. [DOI: 10.1016/j.bmcl.2010.11.010] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2010] [Revised: 10/27/2010] [Accepted: 11/01/2010] [Indexed: 01/12/2023]
|
25
|
Noël R, Shin Y, Song X, He Y, Koenig M, Chen W, Ling YY, Lin L, Ruiz CH, LoGrasso P, Cameron MD, Duckett DR, Kamenecka TM. Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors. Bioorg Med Chem Lett 2010; 21:2732-5. [PMID: 21185177 DOI: 10.1016/j.bmcl.2010.11.104] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2010] [Revised: 11/19/2010] [Accepted: 11/22/2010] [Indexed: 11/18/2022]
Abstract
The design and synthesis of a novel series of c-jun N-terminal kinase (JNK) inhibitors is described. The development of the 4-(pyrazol-3-yl)-pyridine series was discovered from an earlier pyrimidine series of JNK inhibitors. Through the optimization of the scaffold 2, several potent compounds with good in vivo profiles were discovered.
Collapse
Affiliation(s)
- Romain Noël
- Department of Molecular Therapeutics and Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Fang X, Yin Y, Chen YT, Yao L, Wang B, Cameron MD, Lin L, Khan S, Ruiz C, Schröter T, Grant W, Weiser A, Pocas J, Pachori A, Schürer S, LoGrasso P, Feng Y. Tetrahydroisoquinoline Derivatives As Highly Selective and Potent Rho Kinase Inhibitors. J Med Chem 2010; 53:5727-37. [DOI: 10.1021/jm100579r] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Xingang Fang
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| | - Yan Yin
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| | - Yen Ting Chen
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| | - Lei Yao
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| | - Bo Wang
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| | - Michael D. Cameron
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| | - Li Lin
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| | - Susan Khan
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| | - Claudia Ruiz
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| | - Thomas Schröter
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| | - Wayne Grant
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| | | | - Jennifer Pocas
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| | - Alok Pachori
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| | - Stephan Schürer
- Department of Pharmacology and Center for Computational Science, University of Miami, Miami, Florida 33136
| | - Philip LoGrasso
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| | - Yangbo Feng
- Translational Research Institute and Department of Molecular Therapeutics, The Scripps Research Institute, Florida, 130 Scripps Way, 2A1, Jupiter, Florida 33458
| |
Collapse
|
27
|
Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, Ng DC. c-Jun N-terminal kinase (JNK) signaling: Recent advances and challenges. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS 2010; 1804:463-75. [DOI: 10.1016/j.bbapap.2009.11.002] [Citation(s) in RCA: 231] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/18/2009] [Revised: 10/30/2009] [Accepted: 11/02/2009] [Indexed: 11/28/2022]
|